公开(公告)号：US20230338422A1

公开(公告)日：2023-10-26

申请号：US18014627

申请日：2021-07-09

申请人： Nanjing Legend Biotech Co., Ltd.

发明人： Qingling Jiang ,  Yafeng Zhang ,  Shu Wu ,  Chunjing Wu

IPC分类号： C07K14/54 ,  A61P35/00 ,  A61K35/17 ,  C12N15/63

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K14/54 ,  C12N15/63

摘要： The present disclosure relates to a novel platform for immunotherapy which combines CAR or TCR engineered γδ T cells with armoring interleukin IL-36 that can be expressed constitutively or inducibly, or with a chimeric cytokine receptor comprising the endodomain of the IL-36 receptor. The system/platform and the associated methods according to the present disclosure have advantages such as increased immune cell potency and persistence for therapeutic applications.